After CagriSema Blow, Novo Reveals Data for Obesity ‘Triple’

The world of weight loss medicine reached a major turning point in February 2026. Novo Nordisk shared two big sets of results within just twenty-four hours. First, the phase 3 REDEFINE 4 trial showed that CagriSema did not beat out its main rival, tirzepatide. At the same time, the company released positive early data for a new “triple” drug called UBT251.

Obesity affects about 42 percent of adults, leading to serious heart and metabolic problems. Modern GLP-1 drugs changed how doctors treat weight loss by setting a high bar for success. However, tirzepatide has increased the pressure on every other company in the field. Because of this, these new updates from Novo Nordisk are incredibly important for the future of healthcare.

The Redefine 4 Setback Context and Competitive Implications

The REDEFINE 4 study followed 809 adults living with obesity and other health issues. This 84 week trial compared a weekly dose of CagriSema against the popular drug tirzepatide. Both the doctors and the patients knew which medication they were using during the study. Everyone in the trial also followed a plan for better eating and regular exercise.

Patients using CagriSema lost an average of 23.0% of their body weight by week 84. Meanwhile, the group taking tirzepatide saw a higher average weight loss of 25.5%. Therefore, CagriSema failed to prove it was just as good as its main competitor. This news came at a very difficult time for Novo Nordisk and its investors.

Zepbound had already become a top choice for injectable weight loss at the end of 2025. In fact, tirzepatide brought in nearly $5 billion in sales during that single year. This trial result forced experts to look much more closely at Novo’s future growth plans. Given this, the news about the new UBT251 drug was exactly what the company needed to keep people excited.

CagriSema’s dual Mechanism and Existing Regulatory Pathway

CagriSema works by combining two different medicines, cagrilintide and semaglutide, into one injection. Cagrilintide helps people feel full by sending signals to the brain through a specific pathway. Semaglutide works by slowing down how fast the stomach empties after a meal. Together, these two drugs help patients lose more weight than using just one alone.

An earlier study called REDEFINE 1 included over 3,000 adults who did not have diabetes. In that trial, CagriSema helped people lose 20.4% of their weight compared to very little loss with a placebo. Notably, about half of those patients reached a weight that was no longer considered obese. Almost every person in that group lost at least 5% of their total body weight.

In another study, CagriSema helped patients with type 2 diabetes lose 13.7% of their weight. It also helped over 70% of those patients reach their blood sugar goals. Because of these strong results, the company asked federal agencies to approve the drug in late 2025. Officials are currently reviewing it for use in adults with weight related health problems.

UBT251: A New Approach to Weight Loss

UBT251 is a new kind of medicine that targets three different hormones in the body at once. It focuses on GLP-1, GIP, and glucagon to help manage weight and metabolism. Scientists believe that attacking obesity from three angles works better than just using one or two. Early tests show that these three pathways work together to create a powerful effect.

The GLP-1 part of the drug reduces hunger and keeps food in the stomach longer. The GIP part helps the body manage insulin and might even reduce common side effects like nausea. Furthermore, the glucagon part helps the body burn more energy even while at rest. Thus, UBT251 handles hunger, insulin, and energy burning all in one single molecule.

This triple action approach aims to break through the limits of current weight loss treatments. Tirzepatide already showed how well a double action drug can work for many people. Building on this, researchers believe that adding a third hormone could push weight loss even further. The new phase 2 data provides the first real proof that this idea works in humans.

Clinical Trial	Agent Evaluated	Duration	Mean Weight Loss
REDEFINE 4	CagriSema	84 Weeks	23.0%
REDEFINE 4	Tirzepatide	84 Weeks	25.5%
REDEFINE 1	CagriSema	68 Weeks	20.4%
UBT251 Phase 2	UBT251 (6mg)	24 Weeks	19.7%

Phase 2 Evidence and Healthy Outcomes

The latest results for UBT251 were shared with the public on February 24, 2026. This study involved 205 adults who were struggling with their weight and other health conditions. Researchers tested three different weekly doses to see which one worked the best over six months. They watched the participants very closely to ensure the drug was safe and effective.

At the highest dose, patients lost 19.7% of their weight in just 24 weeks. Along with this, the patients saw big improvements in other areas like blood pressure and cholesterol. Their waist sizes got smaller, and their blood sugar levels became much healthier during the trial. These results show that the drug helps with much more than just the number on the scale.

The side effects were mostly what doctors expected from this type of weight loss medicine. Most patients reported some stomach issues, but these were usually mild and did not last long. Most people were able to keep taking the medicine as their bodies adjusted to it. Consequently, there were no new or scary safety concerns found during this phase of testing.

Strategic Context and the Evolving Obesity Pipeline

Releasing data for two different drugs at once was a smart move for the company’s future. Novo Nordisk teamed up with another firm in 2025 to bring UBT251 into their lineup. In light of this, UBT251 is a long term project meant to bridge the gap with competitors. The company now has one drug waiting for approval and another moving through testing.

A larger global study for UBT251 is already happening with about 330 people involved. This study will look even deeper into how the drug travels through the body over time. The company also plans to start testing the drug for people with diabetes later this year. This follows their usual plan of checking if weight loss drugs can help with other diseases.

Meanwhile, the rest of the medical world is looking for easier ways for patients to take medicine. Some companies are working on pills or shots that last even longer than a week. The success of UBT251 could set a brand new standard for how powerful these medicines can be. As a result, Novo Nordisk is staying very active in this fast-moving part of medicine. 

Clinical Positioning and Unmet Need

Even with the recent trial miss, CagriSema is still a very useful tool for many patients. Losing 23% of body weight is still a much better result than older weight loss drugs provided. It also performed better than standard semaglutide in several other clinical trials for diabetic patients. Therefore, CagriSema still holds a valuable spot in the list of available treatments.

The UBT251 data is exciting, but doctors still need to see how it works over a longer time. A six month study is a great start, but weight management is usually a lifelong journey. We also need to see if these results stay the same for people from different backgrounds. Nevertheless, seeing nearly 20% weight loss in such a short time is a huge win.

Right now, the goal is to find out which patients need these powerful triple action drugs the most. People with severe health issues might be the best candidates for this kind of intense treatment. Doctors also want to make sure these drugs are safe to take for many years. Because of this, everyone is waiting for the results of the next, larger clinical trials.

Conclusion

The updates from February 2026 show a mixed but hopeful picture for Novo Nordisk. While CagriSema did not beat tirzepatide, it is still a strong drug with a bright future. The company is still waiting for a final word on its approval later this year. Meanwhile, UBT251 has shown that it might be the next big thing in weight loss.

The science of weight loss is moving fast toward drugs that target multiple hormones at once. Triple action drugs like UBT251 are the newest frontier for researchers and doctors around the world. The intense competition between big drug companies is actually helping patients by creating better medicines faster. These new trial results will help decide how we treat obesity for the next ten years.

In the end, doctors will have to choose the right drug for each individual patient. They will have to think about costs, side effects, and how much weight a person needs to lose. Having more options in the pipeline is always a good thing for people seeking help. Therefore, the next few years will likely bring a total transformation in how we handle metabolic health.

References

Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., & REDEFINE 1 Investigators. (2025). Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine, 393(6), 521–533. https://doi.org/10.1056/NEJMoa2502081

Novo Nordisk A/S. (2025, December 18). Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management [Press release]. PR Newswire. https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html

Novo Nordisk A/S & The United Laboratories International Holdings Limited. (2026, February 24). Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China [Press release]. GlobeNewswire. https://www.globenewswire.com/news-release/2026/02/24/3243205/0/en/Novo-Nordisk-Triple-agonist-UBT251-delivers-up-to-19-7-mean-weight-loss-after-24-weeks-in-phase-2-trial-in-China.html

Novo Nordisk A/S. (2026, February 23). CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity; the primary endpoint was not achieved [Press release]. GlobeNewswire. https://www.globenewswire.com/news-release/2026/02/23/3242381/0/en/Novo-Nordisk-A-S-CagriSema-demonstrated-23-weight-loss-in-an-open-label-head-to-head-REDEFINE-4-trial-in-people-with-obesity-the-primary-endpoint-was-not-achieved.htmlMaters, I. M., Groen, R., Bakker, L. E. H., & Pijl, H. (2025). Triple agonism-based therapies for obesity. Frontiers in Endocrinology, 16, 1563498. https://doi.org/10.3389/fendo.2025.1563498